Supernus Pharmaceuticals (SUPN) Goodwill (2020 - 2026)

Supernus Pharmaceuticals (SUPN) has 7 years of Goodwill data on file, last reported at $120.7 million in Q1 2026.

• Goodwill for Q1 2026 came in at $120.7 million, up 3.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.7 million (up 3.12% YoY), and the FY2025 annual result was $124.9 million, up 6.72% from the prior year.
• Goodwill declined to $120.7 million in Q1 2026 per SUPN's latest filing, from $124.9 million in the prior quarter.
• Over five years, Goodwill peaked at $124.9 million in Q4 2025 and troughed at $115.4 million in Q1 2022.
• A 5-year average of $117.6 million and a median of $117.0 million in 2022 frame the typical range for Goodwill.
• On a YoY basis, Goodwill climbed as much as 50.56% in 2022 and fell as far as 0.42% in 2022.
• A 5-year view of Goodwill shows it stood at $117.0 million in 2022, then changed by 0.0% to $117.0 million in 2023, then changed by 0.0% to $117.0 million in 2024, then gained by 6.72% to $124.9 million in 2025, then retreated by 3.37% to $120.7 million in 2026.
• Business Quant data shows SUPN's Goodwill at $120.7 million in Q1 2026, $124.9 million in Q4 2025, and $119.1 million in Q3 2025.